159 related articles for article (PubMed ID: 30244104)
1. Characterization of Late Acute and Chronic Graft-Versus-Host Disease according to the 2014 National Institutes of Health Consensus Criteria in Japanese Patients.
Ito R; Inamoto Y; Inoue Y; Ito A; Tanaka T; Fuji S; Okinaka K; Kurosawa S; Kim SW; Yamashita T; Fukuda T
Biol Blood Marrow Transplant; 2019 Feb; 25(2):293-300. PubMed ID: 30244104
[TBL] [Abstract][Full Text] [Related]
2. A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-Host Disease by National Institutes of Health Criteria in a Japanese Cohort.
Ohwada C; Sakaida E; Igarashi A; Kobayashi T; Doki N; Mori T; Kato J; Koda Y; Kanamori H; Tanaka M; Tachibana T; Fujisawa S; Nakajima Y; Numata A; Toyosaki M; Aoyama Y; Onizuka M; Hagihara M; Koyama S; Kanda Y; Nakasone H; Shimizu H; Kato S; Watanabe R; Shono K; Sakai R; Saito T; Nakaseko C; Okamoto S
Biol Blood Marrow Transplant; 2020 Jan; 26(1):162-170. PubMed ID: 31536824
[TBL] [Abstract][Full Text] [Related]
3. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
4. Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
Arora M; Cutler CS; Jagasia MH; Pidala J; Chai X; Martin PJ; Flowers ME; Inamoto Y; Chen GL; Wood WA; Khera N; Palmer J; Duong H; Arai S; Mayer S; Pusic I; Lee SJ
Biol Blood Marrow Transplant; 2016 Mar; 22(3):449-55. PubMed ID: 26541363
[TBL] [Abstract][Full Text] [Related]
5. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation.
Thepot S; Zhou J; Perrot A; Robin M; Xhaard A; de Latour RP; Ades L; Ribaud P; Petropoulou AD; Porcher R; Socié G
Leukemia; 2010 Nov; 24(11):1852-8. PubMed ID: 20827288
[TBL] [Abstract][Full Text] [Related]
6. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
7. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
Pawarode A; Mineishi S; Reddy P; Braun TM; Khaled YA; Choi SW; Magenau JM; Harris AC; Connelly JA; Kitko CL; Parkin BL; Goldstein SC; Yanik GA; Levine JE; Ferrara JL; Couriel DR
Biol Blood Marrow Transplant; 2016 Jan; 22(1):54-60. PubMed ID: 26211984
[TBL] [Abstract][Full Text] [Related]
8. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
9. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS
Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
[TBL] [Abstract][Full Text] [Related]
10. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of graft-versus-host disease occurring after alemtuzumab-containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival.
Finazzi MC; Boschini C; Craddock C; Rambaldi A; Ward J; Malladi RK
Br J Haematol; 2020 Feb; 188(4):550-559. PubMed ID: 31713861
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.
Ceberio I; Devlin SM; Sauter C; Barker JN; Castro-Malaspina H; Giralt S; Ponce DM; Lechner L; Maloy MA; Goldberg JD; Perales MA
Leuk Lymphoma; 2015 Mar; 56(3):663-70. PubMed ID: 24913499
[TBL] [Abstract][Full Text] [Related]
13. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study.
Kuzmina Z; Eder S; Böhm A; Pernicka E; Vormittag L; Kalhs P; Petkov V; Stary G; Nepp J; Knobler R; Just U; Krenn K; Worel N; Greinix HT
Leukemia; 2012 Apr; 26(4):746-56. PubMed ID: 21926960
[TBL] [Abstract][Full Text] [Related]
14. Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation.
Miyao K; Kuwatsuka Y; Murata M; Nagafuji K; Teshima T; Takeuchi Y; Shiratori S; Najima Y; Uchida N; Tanaka M; Sawa M; Ota S; Fukuda T; Ozawa Y; Kako S; Kawakita T; Ara T; Tanaka J; Kanda Y; Atsuta Y; Kanda J; Terakura S;
Transplant Cell Ther; 2022 Mar; 28(3):153.e1-153.e11. PubMed ID: 34954151
[TBL] [Abstract][Full Text] [Related]
15. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
17. Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial.
Kitko CL; Braun T; Couriel DR; Choi SW; Connelly J; Hoffmann S; Goldstein S; Magenau J; Pawarode A; Reddy P; Schuler C; Yanik GA; Ferrara JL; Levine JE
Biol Blood Marrow Transplant; 2016 May; 22(5):862-8. PubMed ID: 26551636
[TBL] [Abstract][Full Text] [Related]
18. Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients.
Inamoto Y; White J; Ito R; Martin PJ; Fatobene G; Ito A; Tanaka T; Kurosawa S; Kim SW; Bar M; Sorror ML; Sandmaier BM; Lee SJ; Fukuda T; Flowers MED
Blood Adv; 2019 Sep; 3(18):2764-2777. PubMed ID: 31551243
[TBL] [Abstract][Full Text] [Related]
19. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation.
Kanate AS; Hari PN; Pasquini MC; Visotcky A; Ahn KW; Boyd J; Guru Murthy GS; Rizzo JD; Saber W; Drobyski W; Michaelis L; Atallah E; Carlson KS; D'Souza A; Fenske TS; Cumpston A; Bunner P; Craig M; Horowitz MM; Hamadani M
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1295-1302. PubMed ID: 28412518
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]